Upsher-Smith Launches Generic Fluvoxamine ER, Targets $44.6M US Market
Image
Maple Grove, Minn. – September 30, 2026 -- Upsher-Smith Laboratories, LLC has launched Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths, entering a U.S. market valued at approximately $44.6 million according to IQVIA data covering August 2025 through July 2026.
Upsher-Smith secures AB-rated status against branded Luvox CR
The product carries a Therapeutic Equivalence (TE) code of AB, with Luvox CR designated as the Reference Listed Drug. The AB rating allows the generic to be considered therapeutically equivalent and substitutable for the brand-name extended-release formulation in U.S. pharmacy channels.